|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||44.36 - 45.66|
|52 Week Range||33.06 - 82.68|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2019 - Feb 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.89|
CNBC's Meg Tirrell reports on Esperion shares heading higher on its new cholesterol drug. Esperion CEO and President Tim Mayleben joins 'Power Lunch' to discuss the new drug and drug pricing.
SAN DIEGO, Jan. 29, 2019 -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ:.
SAN DIEGO, CA / ACCESSWIRE / January 7, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR ). Investors, ...
MUNICH , January 7, 2019 /PRNewswire/ -- Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and ...
Esperion Therapeutics Inc. shares soared 11% in premarket trade Friday, after the company said it has reached an agreement with Daiichi Sankyo Europe (DSE) to markt its bempedoic acid in Europe, under which it will receive $300 million in upfront payments and up to $900 million in milestone payments. Bempedoic acid is a cholesterol-lowering agent that works in a similar way to statins. The agreement "seeks to distribute bempedoic acid and the bempedoic acid / ezetimibe combination pill to the millions of patients in these geographies that need additional low-density lipoprotein cholesterol (LDL-C) lowering after maximum tolerated statin therapy," Esperion said in a statement. Shares have fallen 33.6% in the last 12 months, while the S&P 500 has fallen 10%.
Esperion Therapeutics (ESPR) today announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland. The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s European commercial capabilities which includes more than 1000 professionals dedicated to the commercialization of cardiovascular (CV) products, as well as synergies with their existing portfolio of novel oral anticoagulant and antiplatelet products.
ANN ARBOR, Michigan, Jan. 02, 2019 -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,.
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
Biotech stocks may be nearing a significant break out using the SPDR Biotech ETF ( XBI) as a proxy. Esperion has broken out already after rising above technical resistance at $50.75. Now the chart suggests the stock may rise back to $69 to fill that gap, and should that happen it would result in a 17% gain from the current stock price of $58.86.
NEW YORK, NY / ACCESSWIRE / October 26, 2018 / U.S. equities bounced back on Thursday supported mostly by gains in consumer discretionary and technology shares. The Dow Jones Industrial Average jumped ...